The GLP-1 Drug Revolution Is Bigger Than Weight Loss
Ozempic and Wegovy get talked about as weight loss drugs. That framing is increasingly inadequate for what GLP-1 receptor agonists appear to be doing.
The weight loss results are real and significant — patients losing 15 to 20% of body weight in clinical trials far exceeds what any previous pharmaceutical intervention achieved. But the downstream effects are where the story gets more interesting. Large-scale trials have shown meaningful reductions in cardiovascular events — heart attacks and strokes — in patients taking semaglutide, independent of weight loss effects. Separate research is showing promising signals in addiction behavior: patients reporting reduced cravings not just for food but for alcohol, nicotine, and other substances.
The mechanism is not fully understood but appears to involve the drug’s action on reward pathways in the brain, not just the gut hormones that regulate appetite. If GLP-1 drugs are modulating the brain’s dopamine-driven reward system broadly, the implications extend well beyond obesity into addiction medicine, potentially into mental health and neurodegenerative conditions.
Clinical trials are underway for Alzheimer’s, sleep apnea, kidney disease, and liver conditions. Not all of them will succeed. The history of medicine is full of drugs that worked for one thing and failed to transfer. But the breadth of the signals is unusual.
The access problem is significant. These drugs remain expensive, supply has been constrained since demand exploded, and insurance coverage is inconsistent. The people with the most to gain medically from GLP-1 drugs — lower-income, higher-risk populations — are often the least able to afford them.
A drug that might reduce the burden of obesity, cardiovascular disease, and addiction simultaneously would be one of the most consequential pharmaceutical developments in decades. The evidence is not complete. It is compelling enough to pay close attention.